Nora Yang is the Director of Portfolio Management and Strategic Operations at the National Center for Advancing Translational Sciences (NCATS), NIH. In her current role, Nora Yang is responsible for planning, identifying and managing collaboration opportunities and partnerships, developing new business models to improve efficiency and effectiveness of translational sciences, building portfolio and project management capabilities, and implementing best practices of managing public and private partnerships for the NIH National Center for Advancing Translational Sciences (NCATS). She took a leadership role in building and managing the rare and neglected disease drug development portfolio within NCATS, which has taken 4 investigational drugs into rare disease patients in 7 clinical trials within 3 years. Within 4 years, 3 assets within the portfolio have been acquired by pharma partners with a collective deal value of US$1.12 billion. In collaboration with Prof. Andrew Lo at MIT Sloan School of Management and Laboratory for Financial Engineering, Dr. Yang’s current research focus is developing and implementing novel business and financing models that utilize bond market capital for financing biomedical drug development. Global bond market has reached an estimated $82.2 trillion, which has never been used to finance biomedical research due to lack of financial analytic tools to accurately value research backed obligations (RBOs) as a new asset class. Preliminary work from Drs. Lo and Yang’s groups has established both analytic tools and business models ready for private sector implementation.
Prior to joining NCATS at NIH, Dr. Yang led global product development teams to manage and develop novel therapeutics for metabolic diseases and oncology indications at Eli Lilly & Co. and Amgen, Inc. She also worked with startup companies and VC firms to build and evaluate business plans and raise series A funding for startup companies. Nora holds a Ph.D. in molecular biology from the Salk Institute of biological Research and the University of California, San Diego, and a Master’s degree in business management from Stanford University, Graduate School of Business.